Payment overview · 2025
General Payments
$3,655.28
60 reported records · 21 companies
Healthcare provider profile · identity verified
Ayman Elkadry, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · HUNTINGTON, WV · NPI 1861606808
Verified facts
What the public records show
CMS Open Payments records show Ayman Elkadry, MD received $3,655.28 in general payments during 2025 across 60 reported records.
Abbott Laboratories accounted for 43.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Genotropin, Jardiance, Mounjaro, Ozempic, Tepezza, Wegovy.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Prolia by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TEPEZZA as an associated drug or biological on 32661 records involving 9684 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Tepezza by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 1099 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 480 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 904 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 1162 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GENOTROPIN as an associated drug or biological on 864 records involving 515 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Genotropin by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $1,605.13 | 43.9% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $432.29 | 11.8% | 11 | 2025 |
| Senseonics, Incorporated | Unresolved — no canonical attribution shown | $400.00 | 10.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $250.64 | 6.9% | 10 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $162.07 | 4.4% | 6 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$149.02 | 4.1% | 2 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $123.52 | 3.4% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $94.42 | 2.6% | 3 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $78.71 | 2.1% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $74.04 | 2.0% | 4 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $60.36 | 1.6% | 3 | 2025 |
| Amphastar Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $49.64 | 1.4% | 2 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $33.48 | 0.9% | 2 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.43 | 0.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.39 | 0.6% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $19.52 | 0.5% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $19.47 | 0.5% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $17.95 | 0.5% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $15.90 | 0.4% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.90 | 0.4% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $13.40 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,644.61 | 55 |
| Consulting Fee | $1,575.00 | 1 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $400.00 | 1 |
| Education | $24.04 | 1 |
| Travel and Lodging | $11.63 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE PRO Normalized: freestyle libre pro |
Device | Abbott Laboratories | $1,586.63 | 3 | 2025 |
Source payment records
|
|||||
| Eversense Normalized: eversense |
Device | Senseonics, Incorporated | $400.00 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $277.58 | 5 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $235.71 | 9 | 2025 |
Source payment records
|
|||||
| CRENESSITY Normalized: crenessity |
Drug | Neurocrine BioSciences, Inc. | $162.07 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $154.71 | 6 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $149.02 | 2 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $123.52 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $94.42 | 3 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $78.71 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $57.04 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $57.04 | 3 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $40.75 | 2 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $33.48 | 2 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $21.43 | 1 | 2025 |
Source payment records
|
|||||
| GENOTROPIN Normalized: genotropin |
Drug | PFIZER INC. | $20.39 | 1 | 2025 |
Source payment records
|
|||||
| NGENLA Normalized: ngenla |
Drug | PFIZER INC. | $20.39 | 1 | 2025 |
Source payment records
|
|||||
| SOMAVERT Normalized: somavert |
Drug | PFIZER INC. | $20.39 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $19.61 | 1 | 2025 |
Source payment records
|
|||||
| FENSOLVI Normalized: fensolvi |
Drug | TOLMAR, INC. | $19.52 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $19.47 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.50 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $17.95 | 1 | 2025 |
Source payment records
|
|||||
| Saxenda Normalized: saxenda |
Drug | Novo Nordisk Inc | $17.33 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $17.00 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $15.90 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.93 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $13.90 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $13.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GENOTROPIN genotropin |
2025 | Genotropin | 2024 | 91 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 1099 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 480 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 1162 | exact normalized | Medicare Part D |
| TEPEZZA tepezza |
2025 | Tepezza | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
23 | 16 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | TEPEZZA open payments reported associated product |
CMS Open Payments — General Payments 32661 supporting records · 9684 recipient NPIs · example record 1226871638 |
Tepezza · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
1099 | 228 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
480 | 88 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
904 | 188 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
1162 | 220 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
40 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | GENOTROPIN open payments reported associated product |
CMS Open Payments — General Payments 864 supporting records · 515 recipient NPIs · example record 1228794127 |
Genotropin · 2024 Exact normalized brand match · 1 Part D row |
91 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metformin Hcl | Metformin Hcl | 1346 | 304 |
| Ozempic | Semaglutide | 1162 | 220 |
| Jardiance | Empagliflozin | 1099 | 228 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1082 | 222 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1052 | 278 |
| Trulicity | Dulaglutide | 904 | 188 |
| Glimepiride | Glimepiride | 641 | 145 |
| Farxiga | Dapagliflozin Propanediol | 604 | 144 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 568 | 174 |
| Mounjaro | Tirzepatide | 480 | 88 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 477 | 168 |
| Januvia | Sitagliptin Phosphate | 398 | 87 |
| Metformin Hcl Er | Metformin Hcl | 374 | 83 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 356 | 107 |
| Lisinopril | Lisinopril | 344 | 98 |
| Novolog Flexpen | Insulin Aspart | 271 | 86 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 266 | 77 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 258 | 79 |
| Glipizide | Glipizide | 234 | 53 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 223 | 46 |
| Methimazole | Methimazole | 221 | 38 |
| Humalog Kwikpen U-100 | Insulin Lispro | 214 | 70 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 209 | 61 |
| Gabapentin | Gabapentin | 201 | 53 |
| Losartan Potassium | Losartan Potassium | 199 | 52 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 197 | 60 |
| Simvastatin | Simvastatin | 196 | 47 |
| Tradjenta | Linagliptin | 193 | 47 |
| Duloxetine Hcl | Duloxetine Hcl | 159 | 28 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 154 | 34 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 152 | 37 |
| Tresiba Flextouch U-100 | Insulin Degludec | 145 | 38 |
| Amlodipine Besylate | Amlodipine Besylate | 129 | 40 |
| Novolog | Insulin Aspart | 110 | 33 |
| Hydrocortisone | Hydrocortisone | 108 | 20 |
| Fenofibrate | Fenofibrate | 106 | 24 |
| Testosterone Cypionate | Testosterone Cypionate | 105 | 26 |
| Ezetimibe | Ezetimibe | 95 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 94 | 23 |
| Genotropin | Somatropin | 91 | 15 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 90 | 27 |
| Fenofibrate | Fenofibrate Nanocrystallized | 90 | 26 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 89 | 31 |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 88 | 29 |
| Glipizide Er | Glipizide | 72 | 16 |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 66 | 13 |
| Omeprazole | Omeprazole | 65 | 16 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 62 | 20 |
| Gvoke Hypopen 2-Pack | Glucagon | 60 | 25 |
| Vascepa | Icosapent Ethyl | 59 | suppressed |
| Armour Thyroid | Thyroid,pork | 58 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 58 | 17 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 58 | 15 |
| Synjardy | Empagliflozin/Metformin Hcl | 57 | 13 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 55 | 19 |
| Pregabalin | Pregabalin | 52 | 14 |
| Single Use Swab | Alcohol Antiseptic Pads | 52 | 27 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 44 | 19 |
| Wegovy | Semaglutide | 44 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 42 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 42 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 42 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 42 | suppressed |
| Admelog Solostar | Insulin Lispro | 41 | 14 |
| Norditropin Flexpro | Somatropin | 40 | suppressed |
| Rybelsus | Semaglutide | 40 | 14 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 40 | suppressed |
| Carvedilol | Carvedilol | 38 | 11 |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 38 | suppressed |
| Humalog | Insulin Lispro | 37 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 35 | 14 |
| Spironolactone | Spironolactone | 35 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 31 | 16 |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 31 | suppressed |
| Cabergoline | Cabergoline | 30 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 30 | 11 |
| Insulin Lispro | Insulin Lispro | 29 | 11 |
| Propylthiouracil | Propylthiouracil | 29 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Furosemide | Furosemide | 28 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 26 | suppressed |
| Omnitrope | Somatropin | 26 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 26 | 11 |
| Droplet Pen Needle | Pen Needle, Diabetic | 25 | 13 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 25 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 25 | suppressed |
| Fluconazole | Fluconazole | 23 | 13 |
| Prednisone | Prednisone | 23 | suppressed |
| Prolia | Denosumab | 23 | 16 |
| Insulin Aspart Flexpen | Insulin Aspart | 22 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Victoza 3-Pak | Liraglutide | 22 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 21 | 11 |
| Admelog | Insulin Lispro | 20 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Humulin R U-500 | Insulin Regular, Human | 17 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 17 | suppressed |
| Calcitriol | Calcitriol | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Nutropin Aq Nuspin | Somatropin | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | 15 |
| Fiasp | Insulin Aspart (Niacinamide) | 15 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 15 | suppressed |
| Acarbose | Acarbose | 14 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Comfort Touch Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 13 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 13 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 13 |
| Np Thyroid | Thyroid,pork | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Clomid | Clomiphene Citrate | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 12 | suppressed |
| Xyosted | Testosterone Enanthate | 12 | suppressed |
| Dexamethasone | Dexamethasone | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 11 | suppressed |
| Tepezza | Teprotumumab-Trbw | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,655.28 · 60 records | Abbott Laboratories | CRENESSITY, CeQur Simplicity, EVENITY, Eversense, FENSOLVI, FREESTYLE LIBRE 3, FREESTYLE LIBRE PRO, GENOTROPIN, GVOKE HYPOPEN, ISTURISA, JARDIANCE, MINIMED 780G, MOUNJARO, NEXLETOL, NGENLA, Omnipod, Ozempic, QUTENZA, RECORLEV, REZDIFFRA, SOMAVERT, Saxenda, TEPEZZA, TWIIST, Tlando, UNITHROID, Wegovy, Yorvipath, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Genotropin play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error